Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @FierceBiotech
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FierceBiotech
-
Gilead publicly floated the idea of using remdesivir to treat the coronavirus, dubbed 2019-nCoV, 10 days ago. Since then, the effort to advance the drug in the indication has gathered pace.https://www.fiercebiotech.com/biotech/gilead-climbs-as-coronavirus-drug-shows-efficacy-starts-trial …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Craig Basson joins the early-stage private biotech after serving at the Swiss Big Pharma for a decadehttps://www.fiercebiotech.com/biotech/boston-pharmaceuticals-nabs-novartis-veteran-as-new-cmo …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CEPI is supporting programs to develop coronavirus vaccines underway at groups including Inovio Pharmaceuticals and Moderna. The agreement with GSK positions CEPI to expand the support it can offer partner organizationshttps://www.fiercebiotech.com/biotech/gsk-makes-adjuvant-available-to-coronavirus-vaccine-project …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
VX-961 fell at the first hurdle. On Vertex’s fourth-quarter results conference call with investors, Reshma Kewalramani, the company’s chief medical officer, said the phase 1 showed VX-961 lacked the desired pharmacokinetic and tolerability profile.https://www.fiercebiotech.com/biotech/vertex-drops-vx-961-to-continue-search-for-perfect-pain-drug …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Chutes & Ladders—Ex-Takeda exec Ivarsson joins Moderna as CDOhttps://www.fiercebiotech.com/biotech/chutes-ladders-ex-takeda-exec-ivarsson-joins-moderna-as-cdo …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The bad news? These percentages drop for both women and people of color as you look up the ranks. Women make up 30% of executive teams and 18% of biotech company board members, while those numbers are 15% and 14% for people of color, respectively.https://www.fiercebiotech.com/biotech/we-can-do-better-bio-s-first-breakdown-diversity-member-companies …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At the bottom of page 17 of its financial presentation, released as part of its full-year/Q4 results, are three experimental drugs stuck at the bottom of table with a big red arrow pointing down: Translation, they’ve been cut.https://www.fiercebiotech.com/biotech/eli-lilly-cuts-three-cancer-drugs-amid-q4-clear-out …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ivarsson joins Moderna as it drives its hefty pipeline forward. One would think that with 21 programs, Moderna has its hands full. But it looks like the mRNA biotech is planning to build out its pipeline even more.https://www.fiercebiotech.com/biotech/ex-shire-takeda-clinical-trials-chief-melanie-ivarsson-lands-at-moderna …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Details of the departure of the other NME to leave Roche’s pipeline in the fourth quarter emerged earlier this month when Chugai Pharmaceutical disclosed a licensing deal with Verastem Oncology.https://www.fiercebiotech.com/biotech/roche-dumps-antisense-hepatitis-b-drug-after-bagging-rival-asset …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sanofi designed olipudase alfa, a recombinant human ASM, to stop that deterioration by ensuring patients have enough of the enzyme to gradually reduce levels of sphingomyelin. The results shared today validate that hypothesis.https://www.fiercebiotech.com/biotech/sanofi-s-rare-disease-drug-hits-endpoint-teeing-up-2021-filing …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The data are a mixed bag, with the primary endpoint success offset by the failure to improve secondary measures of relevance to the patient population.https://www.fiercebiotech.com/biotech/akcea-pfizer-hit-midphase-goal-but-data-raise-doubts-about-chances-nafld-diabetes …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The priority review applies to advanced RET fusion-positive NSCLC and two types of thyroid cancer.https://www.fiercebiotech.com/biotech/racing-blueprint-lilly-drug-gets-priority-review-for-ret-drug …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
He arrives at Philadelphia-based Century as the biotech nets a new chief technology officer: Greg Russotti, Ph.D., who wore various hats at Celgene, but was most recently vice president of cell therapy development and operations.https://www.fiercebiotech.com/biotech/life-after-novartis-jimenez-joins-board-bayer-backed-cell-therapy-startup …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
There’s a load of trials with its Merck-partnered Bavencio cancer drug that have been felled, but just two experimental trials: PF-06688992 in phase 1 for cancer and PF-04447943, also in phase 1 but for sickle cell anemia.https://www.fiercebiotech.com/biotech/pfizer-cans-early-stage-trials-for-cancer-sickle-cell-targets …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Earlier this month, Sorrento revealed it had received a buyout offer of up to $7 a share, a price that would translate into a deal worth upward of $1 billion.https://www.fiercebiotech.com/biotech/sorrento-rejects-1b-buyout-bid-from-unnamed-private-equity-firm …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Principia’s pipeline is built upon the idea of using BTK inhibitors to curb B-cell attacks against healthy tissues.https://www.fiercebiotech.com/biotech/adrangi-mounts-short-attack-worthless-drugs-sanofi-ally …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
FierceBiotech’s top 5 data readouts in 2020https://www.fiercebiotech.com/special-report/fiercebiotech-s-top-5-data-readouts-2020 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gasdermin D plays a role in multiple inflammatory cell death pathways; when those pathways are activated, the protein forms pores in the cell membrane.https://www.fiercebiotech.com/biotech/quench-bio-emerges-50m-to-treat-severe-inflammatory-disease …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
There has been a war on cancer, but not a war on stroke.https://www.fiercebiotech.com/biotech/jpm-biotech-and-vc-execs-where-industry-should-look-beyond-cancer …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The tenth fund is significantly bigger than its predecessor, which topped out at $419 million in 2017. However, Dan Estes, general partner at Frazier, expects the additional funding to have little effect on the investment approach.https://www.fiercebiotech.com/biotech/frazier-closes-617m-life-science-fund-creating-scope-for-bigger-bets …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.